Triptorelin

Overview

Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) that, like other GnRH agonists, achieves paradoxical suppression of the hypothalamic-pituitary-gonadal (HPG) axis through sustained, non-pulsatile receptor stimulation. First developed in the 1980s, triptorelin has been widely adopted across oncology, reproductive endocrinology, and pediatric endocrinology, particularly in European and international markets.

The compound is available under multiple brand names and formulations:

• Trelstar — intramuscular depot injection (monthly and 6-month formulations; United States)
• Decapeptyl — intramuscular and subcutaneous depot formulations (1-month and 3-month; Europe, Asia)
• Gonapeptyl — subcutaneous depot (Europe)
• Diphereline — various depot formulations (international markets)

Triptorelin shares its fundamental mechanism with other GnRH agonists such as leuprolide and nafarelin, but differs in its specific amino acid substitution, formulation technologies, and pharmacokinetic profile. It is generally considered interchangeable with leuprolide for most indications, though head-to-head comparative data are limited.

Structure and Sequence

Triptorelin is derived from the native GnRH decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) with a single substitution:

• Position 6: Glycine is replaced with D-tryptophan

Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2

• Molecular formula: C64H82N18O13
• Molecular weight: approximately 1,311.5 g/mol
• Salt forms: Available as triptorelin pamoate (Trelstar) or triptorelin acetate (Decapeptyl), affecting formulation but not pharmacological activity
• Key structural features: The D-tryptophan at position 6 confers resistance to endopeptidase cleavage and increases receptor binding affinity approximately 100-fold relative to native GnRH

Mechanism of Action

GnRH Receptor Desensitization

Triptorelin operates through the same biphasic mechanism as other GnRH agonists:

Acute phase (days 1-14):

• High-affinity binding to pituitary GnRH receptors (GnRHR) triggers initial gonadotropin release
• LH and FSH levels increase, causing a transient rise in sex hormones
• Testosterone may increase 50-100% above baseline in males; estradiol rises comparably in females
• This flare effect lasts approximately 1-2 weeks

Chronic phase (from week 2-4 onward):

• Continuous receptor occupancy triggers GnRHR internalization and lysosomal degradation
• Receptor resynthesis is outpaced by internalization, reducing cell-surface receptor density
• Post-receptor signaling pathways (particularly the inositol phosphate/DAG cascade) become desensitized
• Gonadotropin secretion declines to hypogonadal levels
• Testosterone reaches castrate levels (below 50 ng/dL) in approximately 85-95% of patients by day 28
• Estradiol falls to postmenopausal levels in premenopausal women

Tissue-Level Effects

• Prostate: Androgen-dependent cell apoptosis; reduction in prostate-specific antigen (PSA)
• Endometrium: Atrophy of both eutopic and ectopic endometrial tissue
• Pubertal development: Arrest of secondary sexual characteristic progression in central precocious puberty
• Ovarian function: Suppression of folliculogenesis and ovulation

Research Summary

Pharmacokinetics

• Bioavailability (intramuscular depot): essentially complete release from depot matrix over the formulation period
• Half-life (plasma): approximately 3-5 hours after bolus injection
• Depot duration: 1-month (Trelstar 3.75 mg), 3-month (Decapeptyl 11.25 mg), or 6-month (Trelstar 22.5 mg) formulations
• Peak concentration (Cmax): reached within hours of injection; sustained therapeutic levels maintained by depot
• Testosterone suppression: castrate levels typically achieved by day 21-28
• Metabolism: hepatic and renal peptidase degradation; no significant CYP involvement
• Protein binding: not extensively protein-bound
• Excretion: renal elimination of metabolites

Common Discussion Topics

Comparison with Leuprolide

Triptorelin and leuprolide are the two most commonly used GnRH agonist depots. Clinicians and researchers discuss comparative efficacy, with available data suggesting therapeutic equivalence for prostate cancer androgen deprivation. Differences in formulation technology, injection site (intramuscular vs. subcutaneous), and available depot durations influence clinical selection. Some data suggest that triptorelin may achieve testosterone suppression slightly more reliably in certain patient populations, though consensus is that both agents are effective.

Testosterone Breakthrough

A recognized phenomenon with all GnRH agonist depots is "testosterone breakthrough" or "microsurge," where testosterone transiently rises above castrate threshold (typically near the end of the depot period or around the time of re-injection). Triptorelin depot formulations have been evaluated for the incidence of such breakthroughs, with 6-month formulations showing comparable rates to monthly formulations. The clinical significance of transient breakthroughs on prostate cancer outcomes remains under investigation.

Use in Central Precocious Puberty

Triptorelin has a particularly strong evidence base in central precocious puberty, with long-acting (6-month) formulations offering practical advantages in pediatric populations. The 6-month Decapeptyl depot reduces injection burden and improves adherence in children. Long-term follow-up studies have demonstrated preservation of adult height potential and generally favorable safety profiles.

Bone Health Considerations

As with all agents that suppress sex hormones, long-term triptorelin use is associated with decreased bone mineral density. In prostate cancer patients, this is a chronic concern given treatment durations of years. In endometriosis, treatment duration is typically limited to 6 months without add-back hormone therapy to mitigate bone loss. Bisphosphonate or denosumab co-administration is discussed for patients requiring prolonged therapy.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Triptorelin is available under multiple brand names. Always consult a qualified healthcare professional.

Flare management (prostate cancer): Co-administer an anti-androgen for the first 2-4 weeks to mitigate testosterone flare. Monitor testosterone and PSA levels periodically. For precocious puberty, monitor LH, FSH, and sex steroid levels to confirm adequate suppression.

Related Compounds

• Leuprolide — The most widely prescribed GnRH agonist, with similar mechanism but different structural modification (D-Leu6 vs. D-Trp6) and formulation options
• Nafarelin — A GnRH agonist delivered as a nasal spray, offering a non-injectable administration route
• Macimorelin — An oral ghrelin mimetic used in endocrine diagnostics, relevant to the broader context of peptide-based endocrine therapies